News & Views
Merck and Sanofi-aventis laboratories to collaborate on cancer research
Dec 20 2010
In particular, the companies' laboratories will work on testing different combinations of agents that could potentially be used to block specific pathways in cancer cells.
The research will involve Merck Serono's MEK inhibitor MSC1936369B, the PI3K/mTOR inhibitor SAR245409 from Sanofi-aventis and the Class I PI3K inhibitor SAR245408.
Dr Wolfgang Wein, Merck Serono's executive vice-president for oncology, said the need to create more personalised cancer care makes it a "logical step" to explore how "new, exciting molecules" can be combined across development pipelines.
Sanofi-aventis senior vice-president and head of global oncology Dr Debasish Roychowdhury added: "This collaboration reinforces our commitment to maximise our portfolio and to provide better treatments for patients with cancer."
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan